We are live on
!
Find out more
Farallon Capital Management Portfolio holdings
AUM
$21.7B
Turnover
63.92%
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter
Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
(-17%)
Cap. Flow
-$1.58B
Cap. Flow
% of AUM
-8.3%
Top 10 Holdings %
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31
Avg Time Held Equity + Options
1.6
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1
year
Top 20 Avg Time Held Equity only
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Electronic Arts
EA
|
+$492M |
| 2 |
Broadcom
AVGO
|
+$292M |
| 3 |
KKR & Co
KKR
|
+$280M |
| 4 |
Roivant Sciences
ROIV
|
+$248M |
| 5 |
Mastercard
MA
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$650M |
| 2 |
CyberArk
CYBR
|
+$470M |
| 3 |
Salesforce
CRM
|
+$334M |
| 4 |
Nasdaq
NDAQ
|
+$290M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.53% |
| 2 | Miscellaneous | 12.09% |
| 3 | Communication Services | 11.31% |
| 4 | Financials | 11.23% |
| 5 | Technology | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Electronic Arts
EA
| $1.52B | 7.99% |
7,470,000
+2,435,000
| +48% | +$492M |
2025 Q4
1 quarter
|
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $1.5B | 7.85% |
2,300,000
-700,000
| -23% | -$476M |
2025 Q3
2 quarters
|
|
3
Revolution Medicines
RVMD
$40.6B
| $1.32B | 6.94% |
13,604,796
-978,000
| -7% | -$98.8M |
2021 Q1
20 quarters
|
|
4
Amazon
AMZN
$2.75T
| $879M | 4.61% |
4,218,394
-281,500
| -6% | -$62M |
2025 Q2
3 quarters
|
|
5
Microsoft
MSFT
$4.01T
| $868M | 4.55% |
2,344,779
+130,700
| +6% | +$54.7M |
2013 Q3
50 quarters
|
|
6
Aon
AON
$60.8B
| $811M | 4.25% |
2,512,638
-152,600
| -6% | -$50.7M |
2024 Q1
8 quarters
|
|
7
BridgeBio Pharma
BBIO
$13.1B
| $695M | 3.65% |
9,365,463
+367,000
| +4% | +$26.6M |
2024 Q3
6 quarters
|
|
8
PUT
Invesco Aerospace & Defense ETF
PPA
$7.56B
| $691M | 3.62% |
+3,600,000
| New | +$629M |
2026 Q1
0 quarters
|
|
9
Protagonist Therapeutics
PTGX
$8.84B
| $669M | 3.51% |
6,348,906
+204,900
| +3% | +$18.1M |
2017 Q4
33 quarters
|
|
10
Natera
NTRA
$58.3B
| $641M | 3.36% |
3,207,366
-707,000
| -18% | -$152M |
2021 Q2
19 quarters
|
|
11
Exelixis
EXEL
$15.6B
| $562M | 2.95% |
13,111,010
-2,598,490
| -17% | -$112M |
2018 Q3
30 quarters
|
|
|
12
Broadcom
AVGO
$1.64T
| $551M | 2.89% |
1,779,500
+887,100
| +99% | +$292M |
2025 Q4
1 quarter
|
|
13
UnitedHealth
UNH
$365B
| $493M | 2.59% |
1,821,706
+222,800
| +14% | +$66.4M |
2023 Q1
12 quarters
|
|
14
Synopsys
SNPS
$89.7B
| $481M | 2.52% |
1,213,300
+214,100
| +21% | +$96.8M |
2025 Q4
1 quarter
|
|
15
Boston Scientific
BSX
$64B
| $469M | 2.46% |
7,470,684
+31,120
| +0.4% | +$2.49M |
2020 Q3
22 quarters
|
|
16
Thermo Fisher Scientific
TMO
$258B
| $433M | 2.27% |
881,485
+245,800
| +39% | +$133M |
2019 Q4
25 quarters
|
|
|
17
KKR & Co
KKR
$78.7B
| $432M | 2.27% |
4,671,800
+2,654,100
| +132% | +$280M |
2025 Q4
1 quarter
|
|
18
Lantheus
LNTH
$6.53B
| $424M | 2.22% |
5,583,479
+156,000
| +3% | +$11.2M |
2023 Q1
12 quarters
|
|
19
Wabtec
WAB
$48.6B
| $402M | 2.11% |
1,609,403
-866,600
| -35% | -$210M |
2017 Q1
36 quarters
|
|
20
Charles Schwab
SCHW
$163B
| $372M | 1.95% |
3,955,657
+616,000
| +18% | +$60.4M |
2024 Q4
5 quarters
|
|
21
Liquidia Corp
LQDA
$3.11B
| $327M | 1.71% |
8,656,038
| – | – |
2024 Q1
8 quarters
|
|
22
DELISTED
Crinetics Pharmaceuticals
CRNX
| $303M | 1.59% |
8,338,098
+1,405,000
| +20% | +$62.8M |
2023 Q3
10 quarters
|
|
23
Alphabet (Google) Class C
GOOG
$4.22T
| $286M | 1.5% |
996,231
+209,191
| +27% | +$65.7M |
2013 Q2
51 quarters
|
|
|
24
Roivant Sciences
ROIV
$24.6B
| $268M | 1.41% |
9,675,000
+9,638,000
| +26,049% | +$248M |
2023 Q2
11 quarters
|
|
25
Visa
V
$750B
| $254M | 1.33% |
840,710
+144,800
| +21% | +$46.6M |
2016 Q4
37 quarters
|
|
Similar funds
Farallon Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Farallon Capital Management withdrew a net $1.58B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.
- Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
- Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
- Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
- Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
- Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
- Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
- Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.